Amgen is still recruiting patients for a Phase III gout study comparing 2 ways to give pegloticase with methotrexate. The story reports no results or change in treatment availability, so it does not change Amgen's outlook.
The study could help show how pegloticase should be given, but recruitment alone does not show whether patients reached the study's goal. The story reports no results or change in treatment availability, so it does not change Amgen's outlook.
Follow Amgen (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMGN